US EditionPsilocybin Therapy Offers "Paradigm-Changing Alternative" to Conventional Treatment for Depression, Clinical Trials Show
- A single dose of psilocybin has been shown to provide lasting relief from depression and anxiety in cancer patients suffering from major depressive disorder, according to results from a clinical trial.
- Two years post-treatment, 53.6% of patients demonstrated significant depression reduction, with 50% achieving sustained remission.
- At the two-year follow-up, psilocybin reduced anxiety in 42.9% of patients.
- These findings suggest that psilocybin-assisted therapy may serve as a potent and safe alternative to conventional antidepressants for cancer patients' emotional challenges.
33 Articles
33 Articles
Psilocybin for Depressed Cancer Patients; GLP-1s With Clozapine; Global OCD Trip
(MedPage Today) -- A single dose of psilocybin combined with psychological support reduced anxiety and depression for 2 years in people with cancer and major depressive disorder in a phase II trial. (Cancer) The American Psychiatric Association...
For cancer patients with depression, psilocybin may provide lasting relief
A single dose of psilocybin provides long-term reductions in anxiety and depression in cancer patients, a new study shows. Cancer patients can experience depression so severe that it affects their ability to go through treatment. Psilocybin, a chemical in some mushrooms that causes psychedelic effects, has been linked to reductions in depression.
Single-dose of psilocybin shows long-term relief for depression in cancer patients
New results from a clinical trial reveal that a single dose of psilocybin-a naturally occurring psychedelic compound found in mushrooms-can provide sustained reductions in depression and anxiety in individuals with cancer suffering from major depressive disorder.
Single psilocybin trip delivers two years of depression relief for cancer patients
Psilocybin, the active ingredient in magic mushrooms, might just revolutionize how depression and anxiety are treated in cancer patients. In a groundbreaking trial, a single dose combined with therapy significantly reduced emotional suffering, and these effects often lasted over two years. As follow-up studies expand the research to multiple doses and larger samples, scientists are eyeing a possible new standard of care that merges psychedelics …
Coverage Details
Bias Distribution
- 41% of the sources are Center
To view factuality data please Upgrade to Premium
